Navigation Links
CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of,Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1c Reductions Observed in Phase 3 CARISA and MERLIN TIMI-36 Clinical Trials --

PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that researchers have completed preliminary preclinical studies showing that ranolazine increased glucose stimulated insulin secretion in pancreatic beta cells. In separate experiments using preclinical models of insulin resistance, ranolazine also improved glucose homeostasis.

These data could illustrate an underlying first in class mechanism of action for the statistically significant reductions in HbA1c levels observed with Ranexa in cardiovascular patients with diabetes from the phase 3 CARISA (n=189 with angina and diabetes) and MERLIN TIMI-36 (n=2,220 with acute coronary syndromes and diabetes) clinical trials.

In CARISA (Combination Assessment of Ranolazine in Stable Angina), Ranexa (ranolazine extended release tablets) reduced HbA1c levels by an average of up to 0.7 percentage points in angina patients with diabetes. The reduction in HbA1c was not associated with increased hypoglycemia.

"Preclinical studies have shown that Ranexa inhibits the late sodium current in cardiac cells. Potentially, the sodium channels present in pancreatic beta cells may play a role in the secretion of insulin," said Luiz Belardinelli, M.D., senior vice president of pharmacological translational and biomedical research and a distinguished fellow of cardiovascular science at CV Therapeutics.

The company plans to submit data from these new preclinical experiments for publication later this year.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of ca rdiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; dependence on Ranexa; special protocol assessment agreement for Ranexa; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on Form 10-Q for the quarter ended March 31, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

CONTACT: John Bluth, Senior Director, Corporate Communications & InvestorRelations of CV Therapeutics, Inc., +1-650-384-8850

Web site: http://www.cvt.com/

Ticker Symbol: (NASDAQ-NMS:CVTX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
4. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
5. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
6. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... December 7, 2016 According to ... titled , Global Market Study on Multiplex Detection Immunoassay: North ... , the global multiplex detection immunoassay market is expected to witness ... ... ,      (Logo: ...
(Date:12/6/2016)... 6, 2016  Alopexx Oncology, LLC announced data from ... fusion protein (immunocytokine) composed of interleukin-2 and a CD20-targeting ... on B cells as Rituxan and maintains the activities ... also involved in tumor targeting, engagement of the immune ... results of the study (abstract #95954) were presented at ...
(Date:12/6/2016)... 6, 2016 Homozygous Familial Hypercholesterolemia ... Summary Global Markets Direct,s latest Pharmaceutical ... Hypercholesterolemia (HoFH) – Pipeline Review, H2 2016, ... Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape. ... which is caused due to mutation from ...
Breaking Medicine Technology:
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Sharon Kleyne, ... Global Climate Change and Your Health on Voice of America, declared on her radio ... call attention to the fact that when these bullies attack leaders in corporate America, ...
(Date:12/7/2016)... ... 2016 , ... Texas Premier Locksmith , a leading ... unethical locksmith companies and is urging Search Engines to improve verification methods in ... Locksmith, these fraudulent locksmith services take advantage of consumers locked out of houses, ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the 2016 BOC Business Brilliance Awards under the Best New Product Launch category. ... results achieved through user experience. , BOC Global Events & Training Group is ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief ... the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of ... can for this country. , Nancy attributes her patriotic nature to her WWII veteran ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Business ... Summit in Reston, VA on March 21-22, 2017. This premier event features business ... experiences from a cross-section of industries such as financial services, insurance, healthcare, manufacturing, ...
Breaking Medicine News(10 mins):